NasdaqGS:ILMNLife Sciences
Why Illumina (ILMN) Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement
Earlier in January 2026, Illumina announced that the Centers for Medicare and Medicaid Services granted reimbursement for its FDA-approved TruSight Oncology Comprehensive in vitro diagnostic test, setting a US$2,989.55 Clinical Laboratory Fee Schedule rate under PLA code 0543U.
This decision creates a clear reimbursement pathway that could accelerate adoption of comprehensive genomic profiling in everyday oncology practice, particularly across community and regional laboratories that...